{"success":true,"data":{"pressRelease":{"id":"172313","rtpr_id":"nGNXbRDRr5-20261019","ticker":"PBLS","exchange":"NASDAQ","all_tickers":["PBLS"],"title":"Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026","author":"Globe Newswire","published_at":"2026-10-19T11:00:00.438Z","article_body":"Oral presentation will include updated data from the ongoing Phase 1/2 trial,\nwith dose optimization arm designed to inform dose and regimen selection for\nPhase 3 registrational trial in desmoid tumors\n\nCompany to host webcast on Saturday, October 24, 2026, at 6 p.m. CEST / 12\np.m. EDT\n\nCAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines\n(Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to\ncreating extraordinary medicines for patients with serious diseases by\nunlocking historically undruggable targets, today announced that updated\nclinical data for zolucatetide in patients with desmoid tumors will be\npresented at the European Society for Medical Oncology (ESMO) Congress 2026,\ntaking place October 23–27, 2026, in Madrid, Spain.\n\nThe oral presentation will report data from a June 22, 2026, data cutoff,\nincluding data from both the dose escalation and dose optimization portions of\nthe ongoing Phase 1/2 trial. Dose optimization in the desmoid tumor-specific\ncohort is designed to inform selection of the dose and schedule to be carried\nforward into the planned registrational Phase 3 trial of zolucatetide in\npatients with desmoid tumors.\n\nZolucatetide has received both Fast Track Designation and Orphan Drug\nDesignation from the U.S. Food and Drug Administration (FDA) for the treatment\nof desmoid tumors.\n\nPresentation Details\n\nTitle: A phase 1/2 trial of zolucatetide, a first-in-class direct\nβ-catenin:TCF inhibitor: updated safety and efficacy in patients with desmoid\ntumors\n\nAbstract Number: 3715O\nPresenter: Mrinal Gounder, M.D., Memorial Sloan Kettering Cancer Center\nSession: Proffered Paper Session: Sarcoma\nDate & Time: Saturday, October 24, 2026, 14:45–16:15 CEST (8:45–10:15 a.m.\nEDT)\nLocation: Malaga Auditorium - Hall 3, IFEMA Madrid, Madrid, Spain\n\nInvestor Webcast\nParabilis will host an investor webcast on Saturday, October 24, 2026, at\n18:00 CEST (12:00 p.m. EDT) to discuss the updated zolucatetide data that will\nbe presented at ESMO Congress 2026. The webcast will be available on the\nInvestors section of the Parabilis website at\nhttps://investors.parabilismed.com. A replay will be available following the\nevent.\n\nAbout Desmoid Tumors\nDesmoid tumors are locally invasive soft-tissue tumors that arise in\nconnective tissues and can be aggressive and recurrent, often causing chronic\npain, limited mobility, disfigurement and organ dysfunction. An estimated\n30,000 people in the U.S. alone are living with desmoid tumors, including\napproximately 11,000 who are actively managed, with significant unmet need\nglobally as well. Desmoid tumors typically present in young adults, with many\npatients requiring prolonged or intermittent treatment. Wnt/β-catenin\npathway-activating mutations are the causal driver of desmoid tumors, yet no\napproved therapies directly target this underlying biology of the disease.\n\nAbout Zolucatetide \nZolucatetide is an investigational first-in-class and first-and-only direct\ninhibitor of the interaction between β-catenin and the T-cell factor (TCF)\nfamily of transcription factors, a genetically validated driver of numerous\ncancers and other serious diseases that has long been considered undruggable.\nDeveloped using Parabilis’ Helicon™ peptide platform, zolucatetide is\ndesigned to prevent the activation of disease-driving genes by directly\ntargeting β-catenin:TCF, a key downstream node in the Wnt/β-catenin pathway.\nThis approach has the potential to address aberrant Wnt/β-catenin signaling\nregardless of the upstream APC or β-catenin mutations driving pathway\nactivation, potentially overcoming a key limitation of approaches targeting\nearlier steps in the pathway.\n\nZolucatetide is currently being evaluated in an ongoing Phase 1/2 clinical\ntrial (NCT05919264\n(https://www.globenewswire.com/Tracker?data=ycP93UAGiRWmO80xce3QSWw02FoyW-Sr0n6cd8NxEjQiBUMcyNHnIXyhFxWJgPR3Nk2u0Jfh2OLbvYHbIIQ1y1MIBqanqUOoD6sKSmETCGZ1biUdj9wbGqyhfAx316nEkP_PWIyp6ncL5V9qWep1ciALI7pmKDQjRHV4pBgGgcE=))\nacross a range of indications, including desmoid tumors, familial adenomatous\npolyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular\ncarcinoma (HCC) and additional Wnt-driven tumor types.\n\nAbout Parabilis Medicines \n Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical\ncompany dedicated to creating extraordinary medicines for patients with\nserious diseases by unlocking biologically important targets long considered\nundruggable. The Company has pioneered a new class of alpha-helical peptides\n– Helicons™ – capable of modulating intracellular proteins that have\nhistorically been beyond the reach of conventional medicines. The Company’s\nlead investigational medicine, zolucatetide, is the first and only direct\ninhibitor of the β-catenin:TCF interaction, a central node in the\nWnt/β-catenin pathway that has eluded drug developers for decades.\nZolucatetide is being evaluated in the clinic across multiple\nWnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous\npolyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular\ncarcinoma (HCC) and a range of other rare and common solid tumor indications.\nBeyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader\nprogram and advancing additional Helicon-based programs focused on other\nchallenging targets, including ERG and allosteric AR(ON) in prostate cancer,\nwhere we believe our medicines could have life-altering impact. For more\ninformation, visit www.parabilismed.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Q3mxmj3U0J97MPZ6FCgQFno2lVGEm2wy84wM5F65vAbmUrOL0Emng8znMj8Zkozhekxfn7Ocw9msgATFAbW408uAnB7UQDZhGOGBobRghFowBZ9yjGBiGNlS78973U0qoUBrPJ3DdTfL-oqHIupDgfvBZ6sJHQ1AXQi6uigyItKeS27S3JRwsr8T1TDHnDGMCVb4-Un3cq-zyG2ugiZxu4cESOFkSKVKSXTyl63wLkQKhhYJQxIGe5arsEpW3C4erNK2u6vvgFqPvamGeC1tLA==).\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934, each as amended, and the Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified by\nwords such as “designed to,” “expect,” “may,” “plan,”\n“planned,” “potential,” “potentially,” and similar expressions.\nThese statements include, but are not limited to, statements regarding the use\nof data from the dose optimization portion of our Phase 1/2 trial to inform\nthe selection of dose and schedule for our planned Phase 3 registrational\ntrial of zolucatetide in desmoid tumors; the planned Phase 3 trial; and the\npotential of zolucatetide, including its design and potential advantages over\nother approaches.\n\nThese statements are based on management’s current expectations and beliefs\nand are subject to risks and uncertainties that could cause actual results to\ndiffer materially, including: that data from early-stage trials, including\nfrom a specific data cutoff and a limited number of patients, may change with\nadditional patients and follow-up and may not be predictive of later results;\nthat dose and schedule selection may not support, or may require changes to,\nour planned Phase 3 design; that we may not initiate or complete clinical\ntrials as planned, and the FDA or comparable foreign authorities may disagree\nwith our trial design or require additional studies; that zolucatetide may not\ndemonstrate the safety, tolerability or efficacy we expect, and clinical\ndevelopment may be delayed or fail; and other risks described under “Risk\nFactors” in our most recent Quarterly Report on Form 10-Q and our other\nfilings with the U.S. Securities and Exchange Commission. These risks also\napply to forward-looking statements made during the investor webcast.\nForward-looking statements speak only as of the date of this release, and,\nexcept as required by law, we undertake no obligation to update them.\n\nMedia Contact\nJessica Freifeld\nmedia@parabilismed.com\n\nInvestor Contact\nTom Kotarakos\ninvestors@parabilismed.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/544a8a5f-a0fa-4ff4-8891-e9b401e9987a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbRDRr5-20261019","title":"Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026","author":"Globe Newswire","ticker":"PBLS","created":"2026-10-19T11:00:00.438Z","tickers":["PBLS"],"exchange":"NASDAQ","article_body":"Oral presentation will include updated data from the ongoing Phase 1/2 trial,\nwith dose optimization arm designed to inform dose and regimen selection for\nPhase 3 registrational trial in desmoid tumors\n\nCompany to host webcast on Saturday, October 24, 2026, at 6 p.m. CEST / 12\np.m. EDT\n\nCAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines\n(Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to\ncreating extraordinary medicines for patients with serious diseases by\nunlocking historically undruggable targets, today announced that updated\nclinical data for zolucatetide in patients with desmoid tumors will be\npresented at the European Society for Medical Oncology (ESMO) Congress 2026,\ntaking place October 23–27, 2026, in Madrid, Spain.\n\nThe oral presentation will report data from a June 22, 2026, data cutoff,\nincluding data from both the dose escalation and dose optimization portions of\nthe ongoing Phase 1/2 trial. Dose optimization in the desmoid tumor-specific\ncohort is designed to inform selection of the dose and schedule to be carried\nforward into the planned registrational Phase 3 trial of zolucatetide in\npatients with desmoid tumors.\n\nZolucatetide has received both Fast Track Designation and Orphan Drug\nDesignation from the U.S. Food and Drug Administration (FDA) for the treatment\nof desmoid tumors.\n\nPresentation Details\n\nTitle: A phase 1/2 trial of zolucatetide, a first-in-class direct\nβ-catenin:TCF inhibitor: updated safety and efficacy in patients with desmoid\ntumors\n\nAbstract Number: 3715O\nPresenter: Mrinal Gounder, M.D., Memorial Sloan Kettering Cancer Center\nSession: Proffered Paper Session: Sarcoma\nDate & Time: Saturday, October 24, 2026, 14:45–16:15 CEST (8:45–10:15 a.m.\nEDT)\nLocation: Malaga Auditorium - Hall 3, IFEMA Madrid, Madrid, Spain\n\nInvestor Webcast\nParabilis will host an investor webcast on Saturday, October 24, 2026, at\n18:00 CEST (12:00 p.m. EDT) to discuss the updated zolucatetide data that will\nbe presented at ESMO Congress 2026. The webcast will be available on the\nInvestors section of the Parabilis website at\nhttps://investors.parabilismed.com. A replay will be available following the\nevent.\n\nAbout Desmoid Tumors\nDesmoid tumors are locally invasive soft-tissue tumors that arise in\nconnective tissues and can be aggressive and recurrent, often causing chronic\npain, limited mobility, disfigurement and organ dysfunction. An estimated\n30,000 people in the U.S. alone are living with desmoid tumors, including\napproximately 11,000 who are actively managed, with significant unmet need\nglobally as well. Desmoid tumors typically present in young adults, with many\npatients requiring prolonged or intermittent treatment. Wnt/β-catenin\npathway-activating mutations are the causal driver of desmoid tumors, yet no\napproved therapies directly target this underlying biology of the disease.\n\nAbout Zolucatetide \nZolucatetide is an investigational first-in-class and first-and-only direct\ninhibitor of the interaction between β-catenin and the T-cell factor (TCF)\nfamily of transcription factors, a genetically validated driver of numerous\ncancers and other serious diseases that has long been considered undruggable.\nDeveloped using Parabilis’ Helicon™ peptide platform, zolucatetide is\ndesigned to prevent the activation of disease-driving genes by directly\ntargeting β-catenin:TCF, a key downstream node in the Wnt/β-catenin pathway.\nThis approach has the potential to address aberrant Wnt/β-catenin signaling\nregardless of the upstream APC or β-catenin mutations driving pathway\nactivation, potentially overcoming a key limitation of approaches targeting\nearlier steps in the pathway.\n\nZolucatetide is currently being evaluated in an ongoing Phase 1/2 clinical\ntrial (NCT05919264\n(https://www.globenewswire.com/Tracker?data=ycP93UAGiRWmO80xce3QSWw02FoyW-Sr0n6cd8NxEjQiBUMcyNHnIXyhFxWJgPR3Nk2u0Jfh2OLbvYHbIIQ1y1MIBqanqUOoD6sKSmETCGZ1biUdj9wbGqyhfAx316nEkP_PWIyp6ncL5V9qWep1ciALI7pmKDQjRHV4pBgGgcE=))\nacross a range of indications, including desmoid tumors, familial adenomatous\npolyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular\ncarcinoma (HCC) and additional Wnt-driven tumor types.\n\nAbout Parabilis Medicines \n Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical\ncompany dedicated to creating extraordinary medicines for patients with\nserious diseases by unlocking biologically important targets long considered\nundruggable. The Company has pioneered a new class of alpha-helical peptides\n– Helicons™ – capable of modulating intracellular proteins that have\nhistorically been beyond the reach of conventional medicines. The Company’s\nlead investigational medicine, zolucatetide, is the first and only direct\ninhibitor of the β-catenin:TCF interaction, a central node in the\nWnt/β-catenin pathway that has eluded drug developers for decades.\nZolucatetide is being evaluated in the clinic across multiple\nWnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous\npolyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular\ncarcinoma (HCC) and a range of other rare and common solid tumor indications.\nBeyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader\nprogram and advancing additional Helicon-based programs focused on other\nchallenging targets, including ERG and allosteric AR(ON) in prostate cancer,\nwhere we believe our medicines could have life-altering impact. For more\ninformation, visit www.parabilismed.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Q3mxmj3U0J97MPZ6FCgQFno2lVGEm2wy84wM5F65vAbmUrOL0Emng8znMj8Zkozhekxfn7Ocw9msgATFAbW408uAnB7UQDZhGOGBobRghFowBZ9yjGBiGNlS78973U0qoUBrPJ3DdTfL-oqHIupDgfvBZ6sJHQ1AXQi6uigyItKeS27S3JRwsr8T1TDHnDGMCVb4-Un3cq-zyG2ugiZxu4cESOFkSKVKSXTyl63wLkQKhhYJQxIGe5arsEpW3C4erNK2u6vvgFqPvamGeC1tLA==).\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934, each as amended, and the Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified by\nwords such as “designed to,” “expect,” “may,” “plan,”\n“planned,” “potential,” “potentially,” and similar expressions.\nThese statements include, but are not limited to, statements regarding the use\nof data from the dose optimization portion of our Phase 1/2 trial to inform\nthe selection of dose and schedule for our planned Phase 3 registrational\ntrial of zolucatetide in desmoid tumors; the planned Phase 3 trial; and the\npotential of zolucatetide, including its design and potential advantages over\nother approaches.\n\nThese statements are based on management’s current expectations and beliefs\nand are subject to risks and uncertainties that could cause actual results to\ndiffer materially, including: that data from early-stage trials, including\nfrom a specific data cutoff and a limited number of patients, may change with\nadditional patients and follow-up and may not be predictive of later results;\nthat dose and schedule selection may not support, or may require changes to,\nour planned Phase 3 design; that we may not initiate or complete clinical\ntrials as planned, and the FDA or comparable foreign authorities may disagree\nwith our trial design or require additional studies; that zolucatetide may not\ndemonstrate the safety, tolerability or efficacy we expect, and clinical\ndevelopment may be delayed or fail; and other risks described under “Risk\nFactors” in our most recent Quarterly Report on Form 10-Q and our other\nfilings with the U.S. Securities and Exchange Commission. These risks also\napply to forward-looking statements made during the investor webcast.\nForward-looking statements speak only as of the date of this release, and,\nexcept as required by law, we undertake no obligation to update them.\n\nMedia Contact\nJessica Freifeld\nmedia@parabilismed.com\n\nInvestor Contact\nTom Kotarakos\ninvestors@parabilismed.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/544a8a5f-a0fa-4ff4-8891-e9b401e9987a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-19T11:00:00.76330102Z","server_sent_at_ms":1792407600763},"received_at":"2026-10-19T11:00:00.813Z","source_url":null},"analysis":{"id":"160448","press_release_id":"172313","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Parabilis Medicines will present updated Phase 1/2 data for zolucatetide in desmoid tumors in an oral session at ESMO Congress 2026 on October 24, in Madrid.\n\nThe data, with a June 22, 2026 cut-off, will cover both dose escalation and dose optimization arms, which are designed to select the dose and schedule for a planned registrational Phase 3 trial.\n\nZolucatetide holds FDA Fast Track and Orphan Drug designations for desmoid tumors, an indication with an estimated 30,000 U.S. patients and no approved therapy directly targeting Wnt/β-catenin biology. The company will host an investor webcast at 12 p.m. EDT the same day.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Ahead-of-data announcement only -- watch the Oct 24 ESMO oral presentation and webcast for actual Phase 1/2 desmoid tumor efficacy and safety data that will set the Phase 3 dose."},"keyFigures":{"drugName":"zolucatetide","phaseOfTrial":"Phase 1/2","customDimensions":{"abstract_number":"3715O","us_patients_actively_managed":11000,"us_desmoid_tumor_patients_estimated":30000}},"namedEntities":{"people":[{"name":"Mrinal Gounder","role":"Presenter, Memorial Sloan Kettering Cancer Center"},{"name":"Jessica Freifeld","role":"Media Contact"},{"name":"Tom Kotarakos","role":"Investor Contact"}],"products":["zolucatetide","Helicon™ peptide platform"],"companies":[{"name":"Parabilis Medicines","ticker":"PBLS","relationship":"filer"},{"name":"Memorial Sloan Kettering Cancer Center","relationship":"clinical site / presenter affiliation"},{"name":"European Society for Medical Oncology (ESMO)","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of an upcoming data presentation at ESMO with no new clinical results disclosed. Data cut-off June 22, 2026; actual efficacy/safety figures remain unknown until the Oct 24 presentation."},"tickerRelevance":{"others":[],"primary":"PBLS"},"globalImportance":25,"audienceRelevance":22,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"conference data presentation announcement (no new data)","householdBrandBoost":false,"binaryEventPotential":"high -- Phase 3-enabling data readout Oct 24"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Parabilis Medicines will present updated Phase 1/2 data for zolucatetide in desmoid tumors in an oral session at ESMO Congress 2026 on October 24, in Madrid.\n\nThe data, with a June 22, 2026 cut-off, will cover both dose escalation and dose optimization arms, which are designed to select the dose and schedule for a planned registrational Phase 3 trial.\n\nZolucatetide holds FDA Fast Track and Orphan Drug designations for desmoid tumors, an indication with an estimated 30,000 U.S. patients and no approved therapy directly targeting Wnt/β-catenin biology. The company will host an investor webcast at 12 p.m. EDT the same day.","key_figures":{"drugName":"zolucatetide","phaseOfTrial":"Phase 1/2","customDimensions":{"abstract_number":"3715O","us_patients_actively_managed":11000,"us_desmoid_tumor_patients_estimated":30000}},"named_entities":{"people":[{"name":"Mrinal Gounder","role":"Presenter, Memorial Sloan Kettering Cancer Center"},{"name":"Jessica Freifeld","role":"Media Contact"},{"name":"Tom Kotarakos","role":"Investor Contact"}],"products":["zolucatetide","Helicon™ peptide platform"],"companies":[{"name":"Parabilis Medicines","ticker":"PBLS","relationship":"filer"},{"name":"Memorial Sloan Kettering Cancer Center","relationship":"clinical site / presenter affiliation"},{"name":"European Society for Medical Oncology (ESMO)","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-19T11:00:06.119Z","global_importance":25,"audience_relevance":22,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"conference data presentation announcement (no new data)","householdBrandBoost":false,"binaryEventPotential":"high -- Phase 3-enabling data readout Oct 24"}},"durationMs":null,"modelName":"glm-5.3-flashx"}}